Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Heart failure with preserved ejection fraction (HFpEF), is one of the leading causes of
pulmonary hypertension (PH). Despite the severity of this disease, no established treatments
exist for this class of PH. Nebivolol is a drug used in high blood pressure and heart
failure, but not used in patients with PH. Due to some additional properties it possesses,
the investigators believe nebivolol will improve disease severity in patients with PH
associated with HFpEF. The hypothesis of this research study is that nebivolol improves PH
severity in patients with HFpEF, as measured by hemodynamic and clinical parameters.
Phase:
Phase 4
Details
Lead Sponsor:
University of Florida
Collaborator:
National Institute of General Medical Sciences (NIGMS)